195 related articles for article (PubMed ID: 28094760)
1. Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
Lampropoulos CE; Orfanos P; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2017; 35(2):192-200. PubMed ID: 28094760
[TBL] [Abstract][Full Text] [Related]
2. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study.
Lampropoulos CE; Orfanos P; Bournia VK; Karatsourakis T; Mavragani C; Pikazis D; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2015; 33(2):216-24. PubMed ID: 25664400
[TBL] [Abstract][Full Text] [Related]
3. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
4. Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice.
Rodriguez-Rodriguez L; Leon L; Lamas JR; Gomez A; Vadillo C; Blanco M; Jover JA; Abasolo L
Clin Exp Rheumatol; 2016; 34(5):872-879. PubMed ID: 27214094
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.
Baganz L; Richter A; Kekow J; Bussmann A; Krause A; Stille C; Listing J; Zink A; Strangfeld A
Rheumatol Int; 2018 Apr; 38(4):579-587. PubMed ID: 29143933
[TBL] [Abstract][Full Text] [Related]
6. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
Leon L; Gomez A; Vadillo C; Pato E; Rodriguez-Rodriguez L; Jover JA; Abasolo L
Clin Exp Rheumatol; 2018; 36(1):29-35. PubMed ID: 28598787
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
[TBL] [Abstract][Full Text] [Related]
8. Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?
Tan BE; Lim AL; Kan SL; Lim CH; Ng YF; Tng SLC; Hassin NS; Chandran L; Hamid NA; Lee YYL
Rheumatol Int; 2017 Jun; 37(6):905-913. PubMed ID: 28389855
[TBL] [Abstract][Full Text] [Related]
9. The BeSt way of withdrawing biologic agents.
Allaart CF; Lems WF; Huizinga TW
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
[TBL] [Abstract][Full Text] [Related]
10. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
[TBL] [Abstract][Full Text] [Related]
11. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
[TBL] [Abstract][Full Text] [Related]
12. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
Hetland ML; Jensen DV; Krogh NS
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
[TBL] [Abstract][Full Text] [Related]
13. Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.
Cuppen BV; Jacobs JW; Ter Borg EJ; Marijnissen AC; Bijlsma JW; Lafeber FP; van Laar JM;
Clin Exp Rheumatol; 2017; 35(2):221-228. PubMed ID: 27749223
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.
Vassilopoulos D; Delicha EM; Settas L; Andrianakos A; Aslanidis S; Boura P; Katsounaros M; Athanassiou P; Tempos K; Skarantavos G; Antoniadis C; Papazoglou S; Sakkas L; Galanopoulou V; Skopouli F; Boki K; Daoussis D; Vritzali E; Sfikakis PP
Clin Exp Rheumatol; 2016; 34(5):893-900. PubMed ID: 27383049
[TBL] [Abstract][Full Text] [Related]
15. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
17. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
Gabay C; Riek M; Scherer A; Finckh A;
Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
[TBL] [Abstract][Full Text] [Related]
19. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
